Jupiter Acquisition in a regulatory filing included an investor presentation promoting its proposed merger with Filament Health, a Canadian clinical‐stage...
The two companies also shared next steps in their drug testing regimens. The post Atai, Cybin Give Positive Psychedelic Drug Study Updates appeared first...
Atai Life Sciences has completed its Phase 1 study of VLS-01, an oral DMT for treatment-resistant depression (TRD). The post atai Life Sciences Completes...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed. The post News...
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE:7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development...
The global paraxylene market is likely to reach US$ 84.6 million by 2030, with an annual growth rate of more than 5.3%Wilmington, Delaware, Sept. 29,...
The digital world is an integral part of global society, and the online traffic to psychedelic resources can tell us a lot about the state of...
Numinus has announced an at-the-market equity offering program that allows the company to issue and sell up to $10,000,000 (CAD) of common shares. The...
The study found that 100 per cent of patients were responsive and 92 per cent went into remission The post Antidepressants enhance DMT efficacy in patients...
The DMT drug appeared more effective when combined with SSRIs. The post Small Pharma Sees Promise Pairing DMT Drug with Antidepressants appeared first...